Shanghai Shen Lian says UB-221 phase II trial hits primary endpoint
Shanghai Shen Lian Biomedical Corp (SSE:688098) says its Phase II clinical trial of UB-221 met its primary endpoint.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.